GlassScriptPhysician profile
Jay F Schechter
NPI 1740353473
$994.41
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $243 · 2021: $280 · 2022: $59.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.36 | 2019-2021 | |
| Janssen Biotech, INC. | $217.92 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $144.47 | 2020-2022 | |
| Amgen INC. | $91.72 | 2019-2020 | |
| Lilly USA, LLC | $80.31 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $70.12 | 2019-2021 | |
| Ucb, INC. | $55.24 | 2019-2022 | |
| Pfizer INC. | $44.75 | 2021 | |
| Celgene Corporation | $32.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.82 | 2019 | |
| Merck Sharp & Dohme LLC | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.